Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
Investor's Business Daily on MSN48m
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial ResultsNovo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback